A novel compound NSC745885 exerts an anti-tumor effect on tongue cancer SAS cells in vitro and in vivo

  • PLoS One. 2014 Aug 15;9(8):e104703. doi: 10.1371/journal.pone.0104703.
Yuan-Wu Chen  1 ,  Hsu-Shan Huang  2 ,  Yi-Shing Shieh  3 ,  Kuo-Hsing Ma  4 ,  Shing-Hwa Huang  5 ,  Dueng-Yuan Hueng  6 ,  Huey-Kang Sytwu  7 ,  Gu-Jiun Lin  4
Affiliations
  • 1. School of Dentistry, National Defense Medical Center, Taipei, Taiwan, Republic of China; Department of Oral and Maxillofacial Surgery, Tri-Service General Hospital, Taipei, Taiwan, Republic of China.
  • 2. School of Pharmacy, National Defense Medical Center, Taipei, Taiwan, Republic of China; Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan, Republic of China.
  • 3. School of Dentistry, National Defense Medical Center, Taipei, Taiwan, Republic of China.
  • 4. Department of Biology and Anatomy, National Defense Medical Center, Taipei, Taiwan, Republic of China.
  • 5. Department of Biology and Anatomy, National Defense Medical Center, Taipei, Taiwan, Republic of China; Department of General Surgery, Tri-Service General Hospital, Taipei, Taiwan, Republic of China.
  • 6. Department of Neurological Surgery, Tri-Service General Hospital, Taipei, Taiwan, Republic of China.
  • 7. Department of Microbiology and Immunology, National Defense Medical Center, Taipei, Taiwan, Republic of China.
PMID: 25127132 DOI: 10.1371/journal.pone.0104703
Abstract

Objective: Oral squamous cell carcinoma (OSCC) is a prevalent Cancer, especially in developing countries. Anthracyclines and their anthraquinone derivatives, such as doxorubicin, exhibit a cell growth inhibitory effect and have been used as anti-cancer drugs for many years. However, the cardiotoxicity of anthracycline Antibiotics is a major concern in their clinical application. NSC745885 is a novel compound synthesized from 1,2-diaminoanthraquinone, which subsequently reacts with thionyl chloride and triethylamine. The present study aimed to investigate the anti-oral Cancer potential and the safety of NSC745885.

Methods: We investigated the anti-cancer potential of NSC745885 in oral squamous carcinoma cell lines and in an in vivo oral Cancer xenograft mouse model. The expression of apoptotic related genes were evaluated by real-time RT-PCR and western bloting, and the in vivo assessment of apoptotic marker were measured by immunohistochemical staining. The anti-tumor efficiency and safety between doxorubicin and NSC745885 were also compared.

Results: Our results demonstrated that NSC745885 exhibits anti-oral Cancer activity through the induction of Apoptosis in Cancer cells and in tumor-bearing mice, and this treatment did not induce marked toxicity in experimental mice. This compound also exhibits a comparable anti-tumor efficiency and a higher safety in experimental mice when compared to doxorubicin.

Conclusions: The data of this study provide evidence for NSC745885 as a potential novel therapeutic drug for the treatment of human OSCC.

Products